HDE supplement
H050003 S277: Reclaim® DBS Therapy for Obsessive Compulsive Disorder (OCD) System
FDA HDE supplement · 30-day notice · MEDTRONIC INC.,NEUROLOGICAL DIVISION
Key facts
| Original HDE | H050003 |
|---|---|
| Supplement number | S277 |
| Supplement type | 30-day notice |
| Reason for the supplement | process change - manufacturer/sterilizer/packager/supplier |
| Trade name | Reclaim® DBS Therapy for Obsessive Compulsive Disorder (OCD) System |
| Applicant | MEDTRONIC INC.,NEUROLOGICAL DIVISION |
| Received date | Mar 2, 2022 |
| Decision date | Mar 30, 2022 |
At a glance
- No Approval order on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About HDE supplements
An HDE supplement asks FDA to approve a change to a Humanitarian Use Device that already holds a humanitarian device exemption.
Source: U.S. Food and Drug Administration (FDA), Humanitarian Device Exemption (HDE) database · Source date: